sFlt-1/PlGF Ratio: Impact on the Management of Patients With Suspected Pre-eclampsia

Pre-Eclampsia Clinical Trial

— PROSPE  

Official title:

sFlt-1/PlGF Ratio: Impact on the Management of Patients With Suspected Pre-eclampsia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05228002
• Other study ID #: 19-AOI-02
• Status: Recruiting
• Phase: N/A
• Start date: May 23, 2023
• Est. completion date: July 1, 2025

Study information

• Verified date: March 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Julie ANTOMARCHI
• Phone: 04 92 03 60 92
• Email: antomarchi.j[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pre-eclampsia is a specific pathology of pregnancy classically associating arterial hypertension with proteinuria. Its prevalence in industrialized countries is 3 to 8% of pregnancies, which makes it a frequent pathology, and it is responsible for 30% of premature deliveries. The consequences of this pathology can be very serious for the mother:renal insufficiency, hepatic cytolysis, retro-capsular hematoma of the liver, convulsions, disseminated intravascular coagulation. Moreover, the consequences on the fetus and the pregnancy are just as serious: intrauterine growth retardation, induced prematurity, retroplacental hematoma, fetal death in utero.

Pre-eclampsia therefore remains difficult to diagnose and to prognose. The diagnosis of pre-eclampsia based on blood pressure and proteinuria has a predictive value of 30% for adverse outcomes related to pre-eclampsia.

In recent years, new biomarkers have been studied: PlGF, a placental growth factor, and sFlt-1, the free fraction of its membrane receptor.The pathophysiology and specificity of these biomarkers, but especially their ratio, has been widely studied and demonstrated in the diagnosis and prognosis of preeclampsia.

Nevertheless, few studies have analyzed the impact of this report on the hospitalization of patients, except mainly a German study which showed a change in the decision to hospitalize in 16.9% of cases. On the other hand, no French study has been carried out on this subject. Finally, no professional recommendation fully integrates or clearly frames the use of the ratio in current practice. Its use therefore remains disparate between countries, but also within the same country, as in France, where few centers use it.

The decision to hospitalize a patient with suspected preeclampsia depends on the organization of the health care system. It therefore seems interesting to analyze the precise impact on hospitalizations of the use of a diagnostic and prognostic tool such as the sFlt-1/PlGF ratio with the specificities of the French health system, which favors outpatient management.The study would evaluate the use of this promising tool in the daily management of parturients, paving the way for the development of simple recommendations applicable in the various French maternity hospitals.

The hypothesis is that the use of the sFlt-1/PlGF ratio in patients with suspected pre-eclampsia would reduce the rate of hospitalization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: July 1, 2025
• Est. primary completion date: July 1, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pregnant patient

• Affiliated to the Social Security

• Signature of informed consent

• Term > 24 week of amenorrhea and < 37 week of amenorrhea

• Single criterion among the following: (only one box below must be ticked to allow inclusion):

• de novo hypertension (PAS = 140 mmHg and/or PAD = 90 mmHg) ;

• worsening of pre-existing hypertension >10 mmHg (on PAS or PAD ) ;

• worsening of pre-existing proteinuria;

• Excessive edema AND significant weight gain (minimum 2kg/week);

• Headache AND another clinical sign (edema, rapid weight gain);

• Visual disturbances (phosphenes and/or visual blur) AND/OR tinnitus;

• Sudden weight gain (> 1kg/week during the 3rd trimester);

• Low platelet count (thrombocytopenia < 150 G/L);

• Hepatic cytolysis (ASAT and/or ALAT > 2N) without associated pruritus or jaundice;

• Suspicion of intrauterine growth retardation on obstetric ultrasound, with no other cause found (no hypertension or proteinuria, no clinical or biological signs of pre-eclampsia) and no abnormal fetal dopplers.

Exclusion Criteria:

• Minor patient

• Patient with poor clinical tolerance of hypertension and/or need for immediate introduction of intravenous antihypertensive therapy

• Patient with a specific complication of pre-eclampsia requiring immediate management at the time of inclusion: in utero fetal death, retroplacental hematoma, disseminated intravascular coagulation or emergency cesarean section.

• Association of at least 2 of the following criteria:

• De novo proteinuria (24h proteinuria = 0.3 g/24h or P/C ratio = 0.3) or worsening of pre- existing proteinuria;

• Criteria for clinical suspicion of pre-eclampsia: epigastric pain, excessive edema, headaches, visual disturbances, sudden weight gain (> 1kg/week in the 3rd trimester);

• Biological signs associated with pre-eclampsia: low platelet count (thrombocytopenia < 150 G/L), hepatic cytolysis (ASAT and/or ALAT > 2N);

• Suspicion of intrauterine growth retardation on obstetrical ultrasound, with no other cause found.

A combination of at least 2 of these criteria raises the suspicion of pre-eclampsia, and, according to the new CNGOF recommendations of 2024, requires systematic initial hospitalization.

• Vulnerable person requiring enhanced protection, i.e., relatively (or totally) unable to protect their own interests. Specifically, the person's power, intelligence, education, resources, strength, or other attributes necessary to protect his or her own interests may be inadequate (e.g., persons deprived of liberty, minors, persons under guardianship, persons with mental or emotional disabilities in the broadest sense of the word, illiterate persons, refugees and asylum seekers, alcoholics and drug addicts, etc.)

Related Conditions & MeSH terms

• Eclampsia
• Pre-Eclampsia

Intervention

Other:
• sFlt-1/PlGF ratio - Active Comparator: Standard
Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the "standard" group, the biomarker results will be masked and then revealed afterwards for statistical analysis. For the "biomarkers" group, the monitoring decision will be made based on the ratio calculation
• sFlt-1/PlGF ratio - Experimental: Biomarkers
Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the "standard" group, the biomarker results will be masked and then revealed afterwards for statistical analysis. For the "biomarkers" group, the monitoring decision will be made based on the ratio calculation.

Locations

Country	Name	City	State
France	Nice University Hospital	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	hospitalization rate	hospitalization rate for each group.	up to 4 months
Secondary	sFlt-1/PlGF ratio at inclusion and length of hospital stay	correlation between sFlt-1/PlGF ratio at inclusion and length of hospital stay	up to 4 months
Secondary	Complications specific to pre-eclampsia	occurrence of complications specific to pre-eclampsia (eclampsia, HELLP-syndrome, fetal death in utero...)	up to 4 months
Secondary	Pregnancy Outcome	Correlation of the sFlt-1/PlGF ratio at inclusion and its kinetics with pregnancy outcome (route of delivery and urgency criteria)	up to 4 months
Secondary	newborn health status at birth	Correlation of the sFlt-1/PlGF ratio at inclusion and its kinetics with newborn health status at birth (Apgar score and need for immediate pediatric management)	up to 4 months